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Abstract 
There is a need for a methodological approach for allocating health care resources in 
an efficient and fair way that gives legitimacy to decisions. Currently, most priority 
setting approaches tend to focus on single or limited benefit dimensions, even though 
the value of new health care interventions is multi-dimensional. Explicit elicitation of 
social value trade-offs is usually not possible and decision-makers often adopt 
intuitive or heuristic modes for simplification purposes given these multi-criteria 
problems, leading to ad hoc decisions which might diminish the reasonableness and 
credibility of the decisions.  
 
In this paper, we suggest that multi-criteria decision analysis could provide a more 
comprehensive and transparent approach to systematically capture decision-makers’ 
concerns, compare value trade-offs and elicit value preferences. We conclude that 
such methods could inform the development of a facilitated decision support system 
for decision-making in health care, contributing towards a more efficient, rational and 
legitimate resource allocation.   
 
   
 
1 Background 
One of the foremost challenges health care systems are facing is the scarcity of 
resources in combination with rising demand for services, putting their sustainability 
in danger. As a result, decisions relating to the allocation of health care resources has 
been inevitable, either between different competing services and interventions (i.e. 
priority setting) or across different patients (i.e. rationing). However, the 
methodological approach of allocating resources in an efficient and fair way that gives 
legitimacy to decisions has been far from obvious 1-6. This is in large part due to i) the 
complexity of the decisions, as a variety of different factors and objectives need to be 
balanced through the involvement of a range of stakeholders, ii) the importance of the 
decision outcomes, as they have a dramatic impact on human health, and iii) the 
ethical and social responsibilities behind the provision of health care which 
traditionally has been perceived as a government duty, given that health is often 
regarded as a public good or even a human right.   
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2 Resource Allocation Methods in the British National Health Service 
The British National Health Service (NHS) provides an insightful case study of how 
priority setting in health care evolved through the interplay of scientific 
advancements, culture changes and politics. As a result, priority setting today takes 
place across all levels of the organisational hierarchy of the British health care 
system: the central government sets the overall budget of the NHS, commissioners 
and providers determine their purchases among alternative services and interventions, 
and clinicians allocate their time and resources 7.   
Already in 1993 in the UK, “micro-decisions about priority setting [were] constrained 
by macro-decisions about resource allocation taken at superior levels in the 
organisational hierarchy”8 (p.309), in an almost identical landscape where cabinet 
decided on the NHS budget, Department of Health decided the priority targets, and 
purchasers decided on services 8. 
In general terms, in a multi-level context of priority setting, rationing can be 
implemented in various ways: rationing by deterrence, when obstacles to patient 
access are imbedded; rationing by deflection, when the responsibility of service 
provision is passed on to another agency; rationing by dilution, when the quality of 
service declines; rationing by denial, when a particular treatment is refused to get 
funded; and rationing by selection, when a treatment is only allowed for a particular 
population sub-group 7,9. In the UK, rationing by deterrence or delay was possibly the 
first of these models to emerge, with Roy Parker describing this approach in the mid-
70s 10. The other rationing instruments have been applied for at least two decades in 
the country, possibly with the exception of the relatively harsher approaches of 
rationing by denial and selection which became more abundant in recent years due to 
increased fiscal pressures 8. 
The decision-making tool used for budget distribution has not changed either. 
The quality adjusted life year (QALY), which is calculated by multiplying the value 
of each health state by the respective length of time of each state, provides a summary 
measure of total health improvement. It can be used as a simple tool for resolving 
complex choices, and it is the most widely used measure of health status for the 
assessment of health benefits 11-13.  However, it had been argued that the QALY is 
flawed as a way of priority setting in health care 14 and that it only partly reflects an 
individual’s true preferences 15. Furthermore, it has been claimed that the QALY is 
“beset by methodological problems about the valuation of different states of health, 
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by lack of data about incomes, and by the problem of patient heterogeneity” 8 (p.310).  
Klein has therefore claimed that the priority-setting process was not “rational” but 
instead priorities were “emerging from pluralistic bargaining between different 
lobbies, modified by shifting political judgements made in the light of changing 
pressure” 8 (p.310). In doing so though he argued that given the multiplicity of 
conflicting values in such discussions, the idea of “a machine grinding out priorities” 
and making decisions for us would be “absurd”, and that the limitation of pluralistic 
bargaining was that it was not pluralistic enough but instead dominated by some 
(clinical) voices. As a consequence, he suggested that in order for the process to 
become more rational the technical characteristics of the decision-making process 
should be improved, according to an “open dialogue, […], in which arguments can be 
tested against evidence and the conflicts between different values or preferences can 
be explored” 8(p.310), a rationality concept that he acknowledged goes back to 
Aristotle’s work of finding “good reasons” to justify decisions 16.  
A consensus has now been reached that emphasis should be placed on the 
process of decision-making in order to assess the efficiency and fairness of decision 
outcomes. Daniel and Sabin’s Accountability for Reasonableness ethical framework 
has been cited by most for this reason 17, which states that for decisions to be fair and 
legitimate their processes should meet a number of conditions: they should be 
publicly available, based on relevant reasoning, and revisable in light of new 
evidence, all three conditions of which could be assured through enforcement 
mechanisms (i.e. regulation) 18. Given that allocation of resources is also a political 
process, the application of such an ethical framework is very much needed. 
 
 
3 Explicit Priority Setting Efforts in Different Countries 
Priority setting in many countries was introduced through the form of explicit efforts 
taking place between late 80s and early 90s but it was only more recently that its 
necessity was widely acknowledged 19,20, as an insightful review on the priority 
setting efforts of eight countries has indicated 21.  
In the US, the state of Oregon during the late 80s realised that there was no 
effective and accountable way of allocating resources through the Medicaid 
programme. As a result, the Health Services Commission was created in 1989 with 
aim of developing a list of prioritised services that would be entitled to the whole 
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targeted population 22-24. The strategy behind this approach was to ration by excluding 
services, rather than by excluding people. The cut-off threshold on the list of services 
would take place following their cost-effectiveness ranking and up to the point that 
the Medicaid budget allowed for. Due to public dissatisfaction of the emerging 
services, however, the methodology was modified to include more broadly defined 
criteria.  
In the Netherlands, in 1990, the Committee on Choices in Health Care (also 
known as the Dunning Committee) was created for the purpose of priority setting and 
came up with a set of four priority principles: necessity, effectiveness, efficiency and 
individual responsibility 25,26. Necessity referred to whether the intervention could 
provide medical benefit, effectiveness related to the evidence base supporting the 
effect of the intervention, efficiency was a synonym of whether the intervention was 
value for money, and the last principle was meant to deduce whether it would be 
acceptable for services to be paid from individuals themselves. These principles 
should be successively applied in that order (from necessity up to responsibility), 
essentially acting as a strainer for filtering the priority of the services and therefore 
eliminating the non-essential services whose provision would be excluded. The final 
outcome of the so called “Dunning’s funnel” approach was a basic package of 
services that would be funded. 
Similar to the Netherlands, the Parliamentary Priorities Commission was 
implemented in Sweden in 1992 to define a minimum level of health and medical care 
services that could be offered to all its citizens therefore acting as a basic measure of 
“security” 27 and decided that priority setting should take place following a set of 
three core principles: human dignity, need and solidarity, and cost-efficiency 28. 
However, the case of the cost-efficiency principle should only be used to compare 
interventions for the same indication, and measures of effectiveness that incorporate 
quality of life dimensions such as the Quality Adjusted Life Years (QALYs) should 
not be applied across diseases. In 1994, a second committee was convened with the 
aim of eliciting public preferences which up to that time were not reflected at all in 
the process. 
In New Zealand, the National Advisory Committee on Core Health and 
Disability Support Services was established in 1993 to evaluate through discussions 
which services should be included in the publicly funded  health package 29,30. In 
addition to projected budget impact for common conditions and to eligibility criteria 
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for the case of specific services, a set of principles was also set out to guide priority 
setting decisions: equity, efficiency and acceptance. However, further criteria and 
principles, and therefore priorities, emerged following the continuing engagement of 
the Committee with clinicians and members of the public. In 1996 the Committee was 
renamed to National Health Committee (NHC) with the task of meeting annually to 
re-evaluate services based on new evidence. 
It was only following the introduction of explicit efforts in other countries, and 
particularly the New Zealand experience which by some was perceived to be more 
suitable for the British environment due to its “pragmatic” rather than “principle” 
based approach, that the debate in the United Kingdom clearly leaned in favour of 
priority setting  31-35. The Royal College of Physicians itself recommended that a 
National Council for Health Care Priorities should be created "to identify all the 
relevant issues, analyse them publicly and comprehensively, and satisfy all interested 
parties that their views are being considered" 36,37 (p.767).  And although it was clear 
that the driving power behind such an establishment was the fact that resource 
allocation decision problems would never cease to exist due to ever ongoing 
technological advancements and evolving patient expectations, therefore suggesting a 
continuing debate 32, the operational responsibilities and technical characteristics of 
such an institution were still unclear 31. Consequently, the National Institute of 
Clinical Excellence was formed in 1999 (now called the National Institute for Health 
and Care Excellence) with the overall aims of promoting good health and preventing 
and treating ill health while ensuring equity in access and resolving uncertainty 
throughout England and Wales 38. Its responsibilities included the appraisal of new 
and existing health technologies based on clinical and cost-effectiveness grounds, the 
development of clinical guidelines, and the development of audit methodologies. In 
relation to technology appraisals, NICE recommendations are binding to clinical 
commission groups (primary care trusts) which have to fund the respective 
technologies. 
 
4 Resource Allocation and Health Technology Assessment: A Decision Analysis 
Problem  
Due to the different levels at which resource allocation needs to take place, and the 
fact that priority setting is a process focusing on the general population in contrast to 
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the process of rationing which focuses on individual patients, a mix of slightly 
opposing principles act as objectives for resource allocation 7. On the one hand there 
is the purely utilitarian principle of maximising the health impact on the whole 
population 39, and on the other hand there is a set of, usually secondary, ethical 
objectives relating to the distribution of health that mainly aim to prioritise 
interventions which target the more vulnerable 40, such as the poor 41, seriously sick 
42, and women and children 43.  
In theory these objectives could be operationalised through the application of a 
plurality of criteria, most of which are characterising either the intervention under 
consideration or the condition (i.e. disease) it is indicated for. The intervention is 
usually assessed through the notion of benefit risk-ratio, essentially an evaluation 
metric reflecting whether the benefits of implementing the intervention outweigh the 
risks, by accounting both for the impact on health and the impact on resources needed. 
The condition is assessed through its burden or severity, which is usually 
approximated through its seriousness (morbidity and mortality related) and the 
availability of treatments.  
As Baltussen and Niessen have described, a number of such rational priority 
setting approaches have already been developed over the last 20 years, but all of these 
tend to concentrate on single or limited value dimensions 44. These include the dogma 
of evidence based medicine for prioritising interventions according to their 
established effectiveness 45,46, economic evaluation methods (such as cost-
effectiveness analysis) for prioritising according to efficiency by accounting both for 
outcomes and costs 47,48,  burden of disease estimates for prioritising diseases 
according to their burden (through morbidity and mortality)49, budget impact analysis 
for prioritising interventions according to their impact on resources 50 and equity or 
ethical analyses for prioritising according to distributional impact 43. However these 
methodological approaches provide limited support to decision makers given that 
their findings cannot be combined nor can their value trade-offs be elicited, therefore 
not allowing to be appraised and compared altogether 44.  
Most of the current value assessment approaches adopted as part of Health 
Technology Assessment (HTA) mainly consider (comparative) clinical efficacy with 
or without clinical cost-effectiveness, while increasingly incorporating real world 
evidence, therefore capturing value concerns relating to comparative effectiveness and 
efficiency 51. Still, although different countries might assess similar types of evidence, 
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the specific evaluation criteria and endpoints used to derive clinical benefit and 
determine overall value, their level of provision and requirement as well as the way 
they are incorporated (e.g. explicitly vs. implicitly) varies across countries, with their 
relative importance remaining generally unknown 52.   
The value of new health care interventions is multi-dimensional and not 
strictly limited to clinical benefit and cost but spans the disease severity and target 
population size, the nature of the intervention and whether, for example, it is curative 
or preventive, and economic impact and budgetary constraints, alongside other factors 
such as the evidence quality 44,52-54. Therefore, these value assessment methodologies 
are inadequate and at best partial because the evaluation criteria used to assess 
evidence and determine value are incomplete.  Many important social value 
considerations falling under the burden of disease which the treatment addresses, the 
treatment’s innovation level and its overall socioeconomic implications are not 
appropriately incorporated in the evaluation process 55. These value dimensions are 
not always considered, and if they are, this might be done in an implicit and non-
methodical or structured manner, such as through committee deliberation as in the 
case of life-extending end-of-life (EOL) treatments in England with NICE or orphan 
drug modifiers in Scotland with the Scottish Medicines Consortium (SMC) 55,56, thus 
raising important questions about the transparency and consistency of the whole 
process 57.  In addition, there are technical issues in achieving consensus on value, 
including how to derive and incorporate the relative importance of each criterion and 
elicit their value trade-offs.  Ultimately, an explicit definition of value that relies on a 
comprehensive set of parameters is missing in HTA 58 and value could be regarded as 
an elusive concept given that a multitude of evaluation criteria (of varying intensity) 
are applied differently across settings in a non-systematic or transparent manner 52.  
To simplify the complexity of these multi-criteria problems  in value 
assessment and resource allocation, decision-makers might use intuitive or heuristic 
approaches but as a consequence important information might get lost or under-
utilised therefore giving rise to an ad hoc priority setting process 44. It could therefore 
be suggested that they are not well equipped to make well-informed and rational 
decisions under these complex conditions which require the elicitation of multiple 
trade-offs and the construction of value preferences across a range of scientific and 
societal values, which could diminish the reasonableness of the decisions and their 
credibility 59,60.   
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5 Multiple Criteria Decision Analysis in Health Care: An Answer to a Multi-
Criteria Problem? 
The need has arisen for a rational methodological approach that can aid decision-
makers to understand, elicit and construct their preferences across a multitude of 
value concerns in a transparent way. Such an approach could help to improve the 
efficiency of resource allocation decisions across the field of health care with the 
ultimate goal of maximising societal welfare.  
Decision-makers have shown interest in incorporating additional dimensions 
of value through the use of multi-criteria methods 61. These include the European 
Medicines Agency (EMA) for benefit risk assessment 62, the Institute of Medicine in 
the US for prioritising vaccines 63, the Institute for Quality and Efficiency in Health 
Care (IQWiG) in Germany for distinguishing between multiple clinical endpoints 64,  
as well as the National Institute for Health and Care Excellence (NICE) in England 
for the assessment of ultra-rare therapies 65.  As a result, it would be expected that 
decision-makers and other stakeholders would benefit from clear and comprehensive 
ways that allow them to assess all critical value dimensions of new health care 
interventions, in order to make rational decisions about resource allocation and 
priority setting.   
Decision analysis could provide the foundation for an alternative way of 
measuring and eliciting the value of new therapies as it provides a comprehensive 
approach for quantitative modelling 66.  It was originally defined by Howard as “a 
logical procedure” for balancing the factors that influence a decision allowing to 
incorporate values, preferences and uncertainties in a basic structure to model the 
decision 67.  The logic of decision analysis was then described by Raiffa as “divide 
and conquer: decompose a complex problem into simpler problems, get one’s 
thinking straight on these simpler problems, paste these analyses together with logical 
glue, and come out with a program of action for the complex problem” 66 (p.271).   
More specifically, multiple criteria decision analysis (MCDA) has been 
suggested as the most comprehensive approach to quantitative benefit-risk modelling 
of new medicines 68, enabling all favourable and unfavourable effects to be presented 
as quantified utilities or values 69 and has been proposed as a pragmatic way to 
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aggregate different elements of value for the purpose of operationalising value-based 
pricing 70.  
The MCDA methodology acts both as an approach and a set of techniques, 
ordering a set of alternative options by looking at the degree to which a number of 
objectives are achieved 71,72.  It is a way of eliciting preferences for a sum of options 
which are characterised by varying levels of performance with respect to a number of, 
often conflicting, objectives; it does so by disaggregating a complex problem into 
simpler components or objectives, measuring the performance of options against the 
objectives, weighting up these objectives according to their relative importance, and 
re-assembling the components by aggregating scores and weights to show the overall 
picture 66,71. Although a number of different MCDA methodologies and techniques 
exist they share a number of common phases involving the definition of the decision 
problem, understanding of value concerns, identification of alternative options, 
assessment of options’ performance, establishment of value trade-offs between the 
criteria and an overall elicitation of aggregated value preferences for the options 
(Table 1) 71-75.  
 
 
Table 1: The methodological process of Multiple Criteria Decision Analysis  
 
Decision-making phase Decision analysis tasks 
Definition of the decision problem Frame the decision context, analysis aim, 
decision makers and key stakeholders 
Understanding of value concerns 
 
 
Identification of alternative options  
Establish the objectives of the decision-
makers and choose criteria to measure 
them 
Identify the decision alternatives to be 
assessed against the criteria and collect 
evidence on their performance 
Assessment of options performance Describe the consequences of the options 
and score their desirability 
Establishment of criteria value trade-offs  Assign criteria weights to reflect their 
relative importance to the decision 
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Elicitation of overall value preferences Aggregate scores and weights together to 
produce overall weighted value 
preference scores 
 
 
One of the key aims of MCDA techniques is to help decision-makers to reach 
a decision by laying out the problem, objectives, values and options they are faced 
with in a clear and transparent way. This is achieved by organising, synthesising and 
summarising information to decision-makers, which is of complex and, often, of 
conflicting nature 73.  It should be noted however that although MCDA can aid the 
decision-making process, it cannot replace decision-makers’ judgement or experience 
73; instead, it can supply detailed information for a comprehensive set of parameters of 
interest to decision-makers and help them elicit value trade-offs, while allowing to 
incorporate the value preferences of other stakeholders. Overall, MCDA acts as an aid 
to decision-making, seeking to explicitly integrate objective measurement with value 
judgement in a structured and transparent way.   
 
6 Multiple Criteria Decision Analysis as a Decision-Making Tool 
The application of MCDA methods have been proposed for use in the field of health 
care 44,76,77, including for priority setting of health programmes or interventions 78-81, 
the regulatory approval of pharmaceuticals 82-84, and more recently for use in HTA 
57,85-90 and treatment selection 91-93, recognising its potential value in the evaluation  
process and arguing that it could be used as an aid to decision-making. However, 
attention should be paid on the theoretical foundations of decision theory and 
particularly in the required properties the criteria need to possess in order for the 
analysis to be robust and results useful to decision-makers 94-96. 
Compared to economic evaluation methods such as cost-effectiveness analysis 
(CEA), an important advantage of MCDA is that it facilitates a decision support 
system because it enables a structured and transparent process. In CEA, the analysis 
of costs and health gains takes place first as part of the assessment stage, typically 
producing an incremental cost effectiveness ratio (ICER) as a value-for-money 
metric; any value trade-offs (possibly involving other types of benefit gains and 
stakeholder views) are then usually elicited implicitly on an ad hoc basis as part of the 
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appraisal stage, before a decision recommendation can be ultimately made. In 
contrast, in MCDA the analysis for all types of benefit gains and their value trade-offs 
are explicitly incorporated in the overall decision-making process which can be 
formally informed through engagement with stakeholders; overall weighted 
preference value (WPV) scores are produced which are more comprehensive value 
metrics and fully transparent, thus better linking the assessment and appraisal stages 
and supporting decision-making (Figure 1).     
The explicit consideration of decision-makers’ concerns in combination with a 
more structured approach for the elicitation of value preferences and their trade-offs, 
while allowing the incorporation of views from all relevant stakeholders, could inform 
the development of a more comprehensive and reasonable definition of value in health 
care. Such a methodological approach could be used as a supporting tool for 
transparent decision-making, being flexible enough for decision-makers to exercise 
their judgment by enabling them to elicit value trade-offs and their value preferences 
when pursuing multiple objectives, which could contribute to the debate on more 
efficient resource allocation. 
 
 
Figure 1: Differences between cost effectiveness analysis (CEA) and multiple 
criteria decision analysis (MCDA) in decision-making 
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